Today marks the 2nd annual International Stop Wound Infection Day. This day is about raising awareness of effective identification, prevention and management strategies for wound infection.
To this end, we would like to showcase an in vitro study on how DEBRICHEM® is capable of eradicating all viable cells within the biofilm in just one application. DEBRICHEM® works by withdrawing water from the biofilm, rapidly desiccating, and thus disrupting the biofilm and the pathogens in the wound, ultimately allowing the healing process to start through granulation.
The study, carried out by Mathew Mallone, the current Director of Research for the South West Sydney Limb Preservation and Wound Research Academic Unit, summarises the clinical evidence supporting the efficacy of topical desiccating agent DEBRICHEM® in treating the infection in chronic wounds.
The study was published in the International Journal of Molecular Sciences and can be accessed here.
DEBRICHEM® was evaluated in three in vitro models for its efficacy against biofilms produced by Pseudomonas aeruginosa (ATCC-15442) and Staphylococcus aureus (ATCC-6538). The in vitro biofilm models used were; the MBEC Assay®, Centre for Disease Control (CDC) Biofilm Reactor® and a Semi-solid biofilm model. A 30-s exposure of DEBRICHEM® was used in each model.
DEBRICHEM® demonstrated complete eradication of viable cells in all models for both strains (p < 0.0001). Imaging with scanning electron microscopy (SEM) was performed where possible. All three models demonstrated complete eradication of viable cells with a 30 s application of a topical wound desiccating agent.
Results:
DEBRICHEM® demonstrated complete eradication of viable cells in all models for both strains (p < 0.0001). Imaging with scanning electron microscopy (SEM) was performed where possible. All three models demonstrated complete eradication of viable cells with a 30 s application of a topical wound desiccating agent.
Time is tissue; why wait?
DEBRICHEM® is a disruptive new treatment option to address infection in wounds. The topical agent offers a very effective alternative to surgical debridement, the current standard of care.
Please use our contact form to get in touch with our sales representatives or email info@debx-medical.com.